Bristol Myers Squibb checks 'yes' on another Prothena neurodegenerative therapy

Bristol Myers Squibb is again dipping into the well of therapies being developed by Prothena, this time for an exclusive license to a neurodegenerative candidate that is about to slide into human testing.